{"schema_version":"secwatch.filing_event.v1","accession":"0001628280-21-015447","form_type":"8-K","ticker":"VCEL","cik":"0000887359","company_name":"Vericel Corp","filed_at":"2021-08-04T23:59:59+00:00","discovered_at":"2026-05-14T18:04:21.092267+00:00","generated_at":"2026-06-29T22:57:17.819917+00:00","sec_items":["9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Vericel Q2 revenue up 97% to $39.5M; raises FY2021 revenue guidance to $168-171M","bullets":["Total net revenue $39.5M (+97% YoY); MACI $26.5M, Epicel $12.2M, NexoBrid $0.8M.","Net loss narrowed to $3.8M ($0.08/sh) from $8.3M loss; non-GAAP adjusted EBITDA $7.8M (20% margin).","Full-year 2021 revenue guidance raised to $168-171M; adjusted EBITDA margin guided to 23%-25%.","Record quarterly MACI biopsies and Epicel grafting; MACI biopsies up >50% in H1 2021 vs H1 2020.","Cash and investments $116M, no debt; operating cash flow $4.8M in Q2."],"urls":{"canonical":"https://secwatch.observer/filing/0001628280-21-015447","json":"https://secwatch.observer/filing/0001628280-21-015447.json","markdown":"https://secwatch.observer/filing/0001628280-21-015447.md","text":"https://secwatch.observer/filing/0001628280-21-015447.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/887359/000162828021015447/0001628280-21-015447-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/887359/000162828021015447/vcel-20210804.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-29T22:57:17.819917+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}